Can you lose weight on 1.25 mg of tirzepatide — and what does that dose actually do?

Step 1: understand where 1.25 mg sits in the real-world picture

Mounjaro's licensed UK schedule begins at 2.5 mg for the first four weeks. That starting dose isn't a therapeutic target, its job is to let your body adjust to the medicine before the dose rises. The 2.5 mg phase already prompts the dual GIP and GLP-1 receptors that tirzepatide activates, which is why some people notice appetite changes and early weight loss even at this opening level.

The figure 1.25 mg appears in some online discussions because Mounjaro's KwikPen delivers four weekly doses per pen, and some people speculate about injecting half a standard dose, something you can read about in detail on the tirzepatide 1.25 mg page. This is not a licensed approach, and a prescriber would need very specific clinical reasons to advise anything outside the approved schedule. If you're seeing weight-related changes on a low starting dose, that's a sign the medicine is beginning to work, not a reason to stay there longer than your prescription says.

For a fuller breakdown of what the 2.5 mg and 5 mg steps involve, the Mounjaro overview covers the full titration pathway in plain terms.

Step 2: what loss is realistic at the lower end of the dose range

Weight loss on tirzepatide tends to accumulate rather than arrive in one wave. In SURMOUNT-1 (a 72-week randomised trial involving 2,539 adults with obesity) participants lost weight progressively as doses increased, with the most substantial reductions seen at 10 mg and 15 mg. The SURMOUNT-1 paper published in the New England Journal of Medicine reported average body-weight reductions of roughly 15%, 19.5% and 20.9% at the 5 mg, 10 mg and 15 mg maintenance doses respectively.

What that means for a low-dose phase: some loss is possible, particularly in the first weeks when appetite suppression is freshest. But the lower doses are not where the medicine performs best. People who stay at 2.5 mg indefinitely (whether by choice or because of supply difficulties) typically see modest results compared with those who complete titration. The licensed schedule exists because dose escalation is where the medicine's effect really builds.

Curious about whether 5 mg produces meaningful weight loss? That's the first true therapeutic step, and the picture there is clearer.

Step 3: the practical habit that tells you something useful in under a minute

Before each new pen arrives, take your weight at the same time of day, in the same clothes (or none), on the same set of scales. Write it down. That simple weekly check (done consistently) gives your prescriber real data rather than impressions. It's the most useful thing you can do between consultations, and it's often what prompts a well-timed dose increase.

If you're finding that weeks have passed with very little change and side effects have settled, that pattern is worth raising at your next clinical review. Prolonged time at a sub-therapeutic dose isn't the goal. Equally, if nausea or GI upset is significant, moving up too quickly isn't the answer either, your prescriber balances both signals together.

The 5 mg weight loss page explores what clinicians look for when deciding whether to step up. For questions about how the cost of treatment fits into the picture, the Mounjaro price comparison guide sets out the UK private market context honestly.

Step 4: when to talk to your prescriber, and what safety means at any dose

Tirzepatide is a prescription-only medicine regulated by the MHRA, dispensed by pharmacies registered with the GPhC. That means the dose you take should always be the one your prescriber has assessed and approved, not adjusted based on forum advice or supply workarounds. The NHS tirzepatide medicines page summarises the common side effects (nausea, diarrhoea, constipation, indigestion and fatigue are most frequently reported) and notes that they are typically most noticeable after a dose change, often settling within a couple of weeks.

If you experience severe stomach pain that spreads to your back (with or without vomiting) seek medical help promptly; this may indicate pancreatitis, a serious but infrequent side effect the MHRA has flagged in its safety guidance for GLP-1 medicines. Any other concerns, including changes in mood or signs of an allergic reaction, should go straight to a clinician, not a waiting room of strangers online.

Getting the dose right takes a few months and a working relationship with a prescriber who knows your case. Our clinical team at nume reviews every prescription personally (the same day you consult) and continues that clinical oversight at each repeat order. If you'd like a prescriber to assess whether Mounjaro is right for you and at what starting point, check your eligibility with a free consultation.